Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin

Front Immunol. 2023 Sep 20:14:1211505. doi: 10.3389/fimmu.2023.1211505. eCollection 2023.

Abstract

Inflammation is known to play a critical role in all stages of tumorigenesis; however, less is known about how it predisposes the tissue microenvironment preceding tumor formation. Recessive dystrophic epidermolysis bullosa (RDEB), a skin-blistering disease secondary to COL7A1 mutations and associated with chronic wounding, inflammation, fibrosis, and cutaneous squamous cell carcinoma (cSCC), models this dynamic. Here, we used single-cell RNA sequencing (scRNAseq) to analyze gene expression patterns in skin cells from a mouse model of RDEB. We uncovered a complex landscape within the RDEB dermal microenvironment that exhibited altered metabolism, enhanced angiogenesis, hyperproliferative keratinocytes, infiltration and activation of immune cell populations, and inflammatory fibroblast priming. We demonstrated the presence of activated neutrophil and Langerhans cell subpopulations and elevated expression of PD-1 and PD-L1 in T cells and antigen-presenting cells, respectively. Unsupervised clustering within the fibroblast population further revealed two differentiation pathways in RDEB fibroblasts, one toward myofibroblasts and the other toward a phenotype that shares the characteristics of inflammatory fibroblast subsets in other inflammatory diseases as well as the IL-1-induced inflammatory cancer-associated fibroblasts (iCAFs) reported in various cancer types. Quantitation of inflammatory cytokines indicated dynamic waves of IL-1α, TGF-β1, TNF, IL-6, and IFN-γ concentrations, along with dermal NF-κB activation preceding JAK/STAT signaling. We further demonstrated the divergent and overlapping roles of these cytokines in inducing inflammatory phenotypes in RDEB patients as well as RDEB mouse-derived fibroblasts together with their healthy controls. In summary, our data have suggested a potential role of inflammation, driven by the chronic release of inflammatory cytokines such as IL-1, in creating an immune-suppressed dermal microenvironment that underlies RDEB disease progression.

Keywords: dermal microenvironment; epidermolysis bullosa; fibroblast activation; immune suppression; inflammation; interleukin-1; single-cell RNA sequencing; squamous cell carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Squamous Cell* / genetics
  • Collagen / metabolism
  • Collagen Type VII
  • Cytokines / metabolism
  • Epidermolysis Bullosa Dystrophica* / genetics
  • Epidermolysis Bullosa Dystrophica* / metabolism
  • Epidermolysis Bullosa Dystrophica* / pathology
  • Fibroblasts / metabolism
  • Humans
  • Interleukin-1 / metabolism
  • Mice
  • Skin Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Collagen
  • Cytokines
  • Interleukin-1
  • COL7A1 protein, human
  • Collagen Type VII

Grants and funding

The work wassupported by DEBRA UK and DEBRA Ireland (to YL), the Pediatric Cancer Research Foundation (to MSC), and Project PI22/01247, funded by the Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union (to AI). Work by AA was funded by a predoctoral grant contract from the Basque Government. O.I.-S. was funded by a “Programa Investigo” contract of Lanbide-Servicio Vasco de Empleo, cofunded by the European Union (NextGenerationEU).